Effects of exogenous growth hormone administration on dexamethasone‑induced growth impairment in adolescent male rats
- Authors:
- Published online on: August 24, 2017 https://doi.org/10.3892/etm.2017.5017
- Pages: 3455-3462
-
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Growth impairment (GI) is one of the adverse effects of dexamethasone (DXM), and growth hormone (GH) has been used clinically to improve GI. The present study aimed to evaluate the manner in which DXM disturbs the growth rate of longitudinal bones, and the recovery effects of GH on DXM‑induced GI in the longitudinal bones of adolescent male rats. In the first experiment, DXM (0, 0.5, 1, 2 and 5 mg/kg) was administered subcutaneously to identify a potential dose‑dependent activity and calculate the median effective dose (ED50) of DXM‑induced GI. The ED50 was identified to be 1.15 mg/kg. In the second experiment, GH (0, 2.5, 5 and 10 mg/kg) with 1.15 mg/kg DXM was injected subcutaneously to assess the recovery effects of GH on DXM‑induced GI. The growth rates of the longitudinal bones, total height of the growth plate, local mRNA expressions of insulin‑like growth factor 1 (IGF‑1), GH receptor (GHR) and IGF‑1 receptor (IGF‑1R), and local protein expression of IGF‑1 were measured to evaluate the recovery effects of GH on DXM‑induced GI. The local expressions of IGF‑1, GHR and IGF‑1R mRNA, and IGF‑1 protein were measured using quantitative polymerase chain reaction following laser microdissection and antigen‑specific immunohistochemistry, respectively. GH administration partially recovered DXM‑induced GI in the longitudinal bones and growth plate. GH significantly increased the levels of IGF‑1, GHR and IGF‑1R mRNA in the proliferative zone of the control group (P<0.05), whereas it failed to increase them in the proliferative zone of the DXM‑treated group. Furthermore, GH increased the levels of IGF‑1, GHR and IGF‑1R mRNA in the hypertrophic zone of both the vehicle and DXM‑treated groups (P<0.05). Immunohistochemical analysis of IGF‑1 protein expression revealed a similar pattern to that of IGF‑1 mRNA. These results suggest that increased GH insensitivity in the proliferative zone of the growth plate, induced by DXM, leads to GI in longitudinal bones. Thus, combined administration of GH with GH insensitivity‑alleviating medications may be more effective in the treatment of DXM‑induced GI.
